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Centella asiatica (雷公根 lei gong gen) is a traditional medicinal herb with high antioxidant activity, which
decreases amyloid-b (Ab) deposition in the brain. At the same time, aggregated Ab-induced oxidative
stress is the trigger in the pathogenesis of Alzheimer's disease (AD). Here, we investigated the ability of C.
asiatica ethanol extract (CAE) to protect PC12 and IMR32 cells from Ab1e40-induced production of
reactive oxygen species (ROS) and concomitant neurotoxicity. Aggregated Ab1e40 treatment resulted in
reduced cell viability, which can be reversed by cotreatment with 25, 50, and 100 mg/mL CAE. Moreover,
CAE eliminated the Ab1e40-mediated increase in ROS production. Thus, CAE-mediated protection against
aggregated Ab1e40-induced neurotoxicity is attributable to modulation of the antioxidative defense
system in cells, including the activities of superoxide dismutase, catalase, glutathione peroxidase,
glutathione reductase, and levels of glutathione and glutathione disulﬁde by CAE. This emphasizes the
potential therapeutic and preventive value of CAE in the treatment of AD.
Copyright © 2016, Center for Food and Biomolecules, National Taiwan University. Production and hosting
by Elsevier Taiwan LLC. This is an open access article under the CC BY-NC-ND license (http://
creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Amyloid b (Ab) peptides have been proposed as the pathogno-
monic indicators of the pathogenesis of Alzheimer's disease (AD),
the most prevalent neurodegenerative disease worldwide, which is
characterized by impaired memory and loss of neurons in the
central nervous system.1,2 Ab peptide, a byproduct of the degra-
dation process of amyloid precursor protein (APP), consists of two
major peptides of varying lengths: Ab1e40 and Ab1e42. Plasma
concentrations of Ab1e40 and Ab1e42 increase with age and are
elevated in individuals with mutations that cause early-onset AD.
Both peptides are important components of plaques in AD and have
been proposed to induce neuronal death and neurotoxicity in both
in vivo and in vitro studies.3e5 A primary Ab1e40 mechanism of ac-
tion is the induction of excess reactive oxygen species (ROS),
including superoxide, hydrogen peroxide (H2O2), and singlet oxy-
gen. This increase in intracellular ROS causes oxidative stress.; fax: þ886 2 3366 3838.
for Food and Biomolecules,
molecules, National Taiwan Unive
ons.org/licenses/by-nc-nd/4.0/).Moreover, a combination of Ab-mediated ROS induction and
excessive Ca2þ inﬂux has been reported to lead to neuronal loss and
cellular apoptosis.6 Given the importance of ROS-related mecha-
nisms in AD, several studies have used antioxidants, such as
vitamin E7 and Ginkgo biloba (銀杏 yín xìng) extract,8 or have
enhanced the activities of enzymes in the antioxidative defence
system, such as superoxide dismutase (SOD), catalase, glutathione
peroxidase (GPx), and glutathione reductase (GR)9 to protect
neuronal cells from the Ab-induced ROS. These studies have shown
that use of antioxidants and activation of the antioxidative defence
system could suppress the neurotoxicity of Ab in in vivo and in vitro
models. Therefore, agents capable of attenuating oxidative stress
may contribute to a superior therapeutic strategy for the treatment
of Ab-induced neurotoxicity and may lead to improved neurolog-
ical outcomes in AD.
Centella asiatica (雷公根 lei gong gen), a member of the family
Apiaceae (Umbelliferae), has been used as a traditional medicinal
herb in Asia for over 2000 years. A number of medicinal functions
and biological activities have been found in C. asiatica, both in the
whole plant and its extract, including the ethanolic and aqueous
extracts. The major active components of C. asiatica ethanol extract
(CAE) are the triterpenoids, including asiatic acid and asiaticoside.10rsity. Production and hosting by Elsevier Taiwan LLC. This is an open access article
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scavenging 2,2-diphenyl-1-picrylhydrazyl (DPPH), reducing Fe3þ,11
and activating the antioxidative defence system in the brain.12
Feeding aged rats CAE for 60 consecutive days delayed the aging
process by improving oxidative status and reducing lipid peroxi-
dation in the rat brain.12 Additionally, CAE has been used in the
treatment of neurodegenerative diseases, such as AD. CAE could
enhance the capability of rats in performing several memory tasks,
including the Morris water maze and the passive avoidance test.13
The use of CAE in an AD transgenic mouse model was reported to
reduce the deposition of Ab in the hippocampus and improve the
behavioral symptoms of mice.14,15 However, the mechanism un-
derlying the inhibition of Ab deposition or prevention of Ab
neurotoxicity remains unclear.
The rat pheochromocytoma (PC12) cells are commonly used in
the neuronal cell study. It is well known that exogenous stimuli
such as Nerve Growth Factor (NGF) induce neurite outgrowth.
Many studies looking to elucidate mechanisms involved in
neuronal gene expression have been conducted in PC12 cells as
these cells take on a cholinergic phenotype when differentiated
with NGF. However, the IMR32 cell line has been identiﬁed for
studying tau regulation as these cells have been shown to develop
ﬁbrillar structures that react to imunoprobes for paired helical ﬁl-
aments, the main constituents of neuroﬁbrillary tangles. In theory,
IMR32 cells being of human neuronal origin may be a more
appropriate cell line to study APP-processing in relation to Alz-
heimer's disease than the rat phaeochromocytoma PC12 cell line.
Therefore, these detected differences warrant further investigation.
To understand how CAE modulates Ab-mediated neurotoxicity, we
investigatedwhether the addition of CAE to differentiated PC12 and
IMR32 cells expressing aggregated Ab1e40 could affect Ab1e40-
induced cell death and excessive ROS generation. We also
measured cellular levels of a variety of antioxidative enzymes and
oxidative molecules, including SOD, catalase, GPx, GR, glutathione
(GSH), and glutathione disulphide (GSSG), to further deﬁne the
CAE-mediated enhancement of the antioxidative defence system in
AD.
2. Materials and methods
2.1. Preparation of aggregated Ab peptide
The Ab1e40 aggregationmethodwasmodiﬁed from our previous
study.16 One milligram of Ab1e40 peptide was dissolved in
phosphate-buffered saline (PBS, pH 7.4) at a concentration of
500 mM and incubated at 37 C for 24 h. After incubation, the
peptide was stored at 20 C as the stock solution. To prepare the
aggregated Ab1e40 peptide solution, the stock solution was diluted
to 230 mM by PBS and incubated at 37 C for 7 days. In all experi-
ments, the aggregated Ab1e40 peptide solution was diluted to the
indicated experimental concentrations by cell culture medium.
Conﬁrmation of the aggregated Ab peptide was measured by the
thioﬂavin T (ThT) Ab1e40 aggregation kit (Ana Spec Inc., Fremont,
CA, USA). The aggregation of Ab1e40 in the presence and absence of
50 mM morin and tannic acid, known inhibitors of ﬁbril formation.
Reactions were assembled at a ﬁnal volume of 100 mL at room
temperature in a black 96-well plate according to the assay
protocol.
2.2. Preparation of C. asiatica ethanolic (雷公根 lei gong gen)
extract (CAE)
The whole dried C. asiatica plant provided by Wei Chuan Cor-
poration (Taipei, Taiwan) was ground into powder by a homoge-
nizer (Model PRO 200; PRO Scientiﬁc Inc., Oxford, CT, USA). Tengrams of C. asiatica powder was soaked in 100 mL of 20% ethanol
and incubated at 37 C for 1 day. The ethanolic extract was ﬁltered
and freeze-dried and the ﬁnal CAE powder was stored in the dark
at 20 C until use.2.3. HPLC analysis of C. asiatica extracts active compounds
C. asiatica (1 g) was extracted with 10 mL of 20 % ethanol at
37 C for 24 h. The extract was ﬁltered with a 0.45-mm ﬁlter and
analyzed by HPLC. HPLC analyses were performed on a LC-2000
series apparatus (Jasco) with a PU-2089 plus pump and a MD-
2010 plus diode array detector, equipped with a LUNA C18 col-
umn (250  4.6 mm inner diameter; 5-mm particle size; Phe-
nomenex, Torrance, CA, USA). The wavelength of diode array
detector was set at 206 nm. The analytical method was based on
previous study.172.4. PC12 and IMR32 cell culture and treatment
Rat PC12 pheochromocytoma cells and human IMR32 neuro-
blastoma cells were purchased from Bioresource Collection and
Research Center (BCRC, Hsinchu, Taiwan). PC12 cells were
cultured in Roswell Park Memorial Institute (RPMI) 1640 medium
with 10% horse serum (HS), 5% fetal bovine serum (FBS), and
2 mM L-glutamine at 37 C in a 5% CO2 humidiﬁed environment.
IMR32 cells were cultured in minimum essential media (MEM)
medium with 10% FBS at 37 C in a 5% CO2 humidiﬁed environ-
ment. Poly lysine was prepared by adding 50 mL sterile tissue
culture grade water to 5 mg poly lysine. Coated cell culture sur-
face with 1 mL/25 cm2 culture surface. After 15 min removed
solution by aspiration and thoroughly rinsed surface with sterile
tissue culture grade water. Finally, the cell culture was sterilized
under the hood and UV light for 10e15 min. PC12 cells were
seeded on poly-L-lysine-coated plates and cultured for 24 h, fol-
lowed by culturing in the medium containing 100 ng/mL nerve
growth factor for 6 days. Differentiated PC12 cells were treated
with or without aggregated Ab1e40 peptide in the presence of CAE
(0, 25, 50, or 100 mg/mL).2.5. 1,3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium
bromide (MTT) cell viability assay
Differentiated PC12 and IMR32 cells seeded in 24-well plates
(5  104 cell/well) were incubated with culture medium con-
taining CAE (0, 25, 50 or 100 mg/mL) for 24 or 48 h and then the
cells were incubated with 1,3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide (MTT) (0.5 mg/mL) at 37 C in the
dark for 2 h. The optical density (OD) of each well was determined
by the microplate reader (F3; Molecular Devices, Sunnyvale, CA,
USA) at a wavelength of 570 nm after dissolving with dimethyl
sulphoxide.2.6. 5,5ʹ-dithiobis-2-nitrobenzoic acid (DTNB), 2,7-
dichloroﬂuorescin diacetate (DCFH-DA) ﬂuorescent assay
DCFH-DA was used as a ROS probe to monitor the intracellular
accumulation of ROS. To measure ROS production, differentiated
PC12 cells seeded in 12-well plates (1 105 cell/well) were treated
with aggregated Ab1e40 and CAE (0, 25, 50 or 100 mg/mL) for 6 and
24 h. After treatment, the cells were collected, washed twice with
phosphate buffered saline (PBS), and stained with DCFH-DA for
30 min, then the cells were washed and analyzed by ﬂow
cytometry (FACSCanto II; BD Biosciences, Franklin Lakes, NJ, USA).
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The activity of SOD, catalase, GR and GPx were determined in
cell samples (by triplicate each one) using commercial kits (Cayman
Co., Ann Arbor, MI, USA) following the manufacturer's protocol for
each kit. The data were expressed as relative percentages of the
control group which was not treated with CAE and Ab1e40.
2.8. Measurement of intracellular GSSG and GSH concentrations
To measure the concentration of GSH, 10 mL of cell lysate was
mixed with 95 mL reaction solution containing 2 U/mL GR,
200 mM nicotinamide adenine dinucleotide phosphate (NADPH),
and 2 mM ethylenediaminetetraacetic acid (EDTA). After adding
100 mL DTNB (10 mM dissolved in 50 mM phosphate buffer, pH
7.2) to the mixture, the OD value at 405 nm was measured at 1-
min intervals for 5 min. The GSH concentration was calculated
by a GSH standard curve. To measure the concentration of GSSG,
70 mL cell lysate was mixed with 4 mL 1-methyl-2-vinylpyridinium
triﬂuoromethanesulphonate (M2VP; 10 mM) and incubated for
1 h to remove GSH in the lysate. The lysate was then treated as
described above for the measurement of GSH, and the GSSG
concentration was calculated by a GSSG standard curve.
2.9. Statistical analysis
All data were expressed as mean ± standard deviation (SD).
Statistical analysis was calculated with one-way analysis of vari-
ance (ANOVA), followed by Duncan's test, which was provided by
SPSS13.0 statistical software (SPSS Institute, Inc., Chicago, IL, USA).
The P value of two groups less than 0.05 was considered as
signiﬁcantly different between the values compared.
3. Results
3.1. Effect of CAE on Ab1e40-induced neurotoxicity in differentiated
PC12 and IMR32 cells
We ﬁrst treated differentiated PC12 and IMR32 cells with CAE
alone to examine their toxicity. Cell viabilities of differentiated
PC12 and IMR32 cells were maintained above 85.5% and 133.3%,
respectively, upon treatment with varying concentrations of CAE
for 24 and 48 h. Results indicate that CAE was not signiﬁcantly
cytotoxic (P > 0.05 versus control for both) at concentrations of
less than 100 mg/mL (Table 1). Therefore, we selected a CAE con-
centration in the range of 25e100 mg/mL for subsequent
experiments.
Treatment of differentiated PC12 cells with varying concentra-
tions of aggregated Ab1e40 (2e12 mM) signiﬁcantly reduced the cell
viability of differentiated PC12 cells; after 24 h, from 79.5% at 2 mMTable 1
The effect of CAE treatment on the viability of differentiated PC12 and IMR32 cells.
Group CAE concentration (mg/mL)
0
Cell viability (%)
PC 12 24 h 100.3 ± 6.2
IMR32 102.2 ± 1.6
PC 12 48 h 100.2 ± 5.9
IMR32 103.3 ± 3.1
*P < 0.05 compared to control; increase in cell viability. **P < 0.05 compared to control,
CAE: Centella asiatica 20% ethanol extract.to 62.2% at 12 mM (P < 0.05, Fig. 1A). Treatment of IMR32 cells with
varying concentrations of aggregated Ab1e40 (0.4e2.8 mM) signiﬁ-
cantly reduced the cell viability of IMR32 cells; after 24 h, from
96.5% at 0.4 mM to 60.3% at 2.8 mM (P < 0.05). When the concen-
tration of aggregated Ab1e40 exceeded 2.0 mM, cell viability was
reduced to less than 56.5% after 48 h (Fig. 1B). These results indicate
that IMR32 cells were more sensitive than PC12 cells to Ab1e40-
induced cell toxicity.
To monitor the effect of CAE on Ab1e40-induced neurotoxicity in
differentiated PC12 cells, cells were treated with 8 mM aggregated
Ab1e40 in the presence of varying concentrations of CAE. We
observed that without CAE cell viability of differentiated PC12 cells
was signiﬁcantly reduced to 67.8% and 60.4% at 24 and 48 h after
Ab1e40 treatment, respectively (P < 0.05 versus control, Fig. 1C). We
also observed that the neurotoxicity of aggregated Ab1e40 was
signiﬁcantly diminished by treatment with CAE in the concentra-
tion range of 25e100 mg/mL at 24 h (P < 0.05 versus Ab1e40 treat-
ment alone, Fig. 1C), indicating that CAE could protect
differentiated PC12 cells from aggregated Ab1e40-induced neuro-
toxicity. Interestingly, this protective effect became less signiﬁcant
when cells were treated for 48 h, except for the 100 mg/mL CAE
treatment (Fig. 1C). Viability of IMR32 cells was signiﬁcantly
reduced to 66.9%, 77.0%, and 70.2% at 24 h; 68.6%, 79.0%, and 68.9%
at 48 h, respectively after treating with 2.0 mM aggregated Ab1e40
(P < 0.05 versus control, Fig. 1D). Furthermore, the addition of CAE
in the concentration range of 25e100 mg/mL signiﬁcantly protected
IMR32 cells from the neurotoxicity induced by aggregated Ab1e40 at
24 and 48 h (P < 0.05 versus Ab1e40 treatment alone, Fig. 1D).3.2. Chromatogram of C. asiatica (雷公根 lei gong gen) extracts in
high performance liquid chromatography (HPLC)
We calculated the content in CA extracts with HPLC. After
comparing the chromatogram of CA extracts with four standard
solutions, including madecoside (MS), asiaticoside (AS), madecassic
acid (MA) and asiatic acid (AA), we conﬁrmed that MS and AS were
present, but not MA and AA. After quantitative analysis, MS content
accounted for 1.20% of the CA extracts, while AS content accounted
for only 0.17%. Because the most effective dose in CA extracts was
50 mg/mL, we used this concentration to calculate themost effective
concentration of MS and AS. Using this value, the concentration of
MS was found to be 6.0 mg/mL, calculated as 50 mg/mL  1.20%,
while the concentration of AS was 0.085 mg/mL, calculated as 50 mg/
mL  0.17% (Fig. 2A and B).3.3. Effect of CAE on Ab1e40-stimulated ROS production
Accumulation of ROS in cells is an important index for moni-
toring the neurotoxicity caused by aggregated Ab1e40. Aggregated
Ab1e40 treatment for 6 and 24 h signiﬁcantly increased ROS levels25 50 100
119.3 ± 4.9* 90.5 ± 3.5** 85.5 ± 0.5**
109.2 ± 2.4* 112.4 ± 2.5* 121.2 ± 2.6*
101.4 ± 4.5 96.9 ± 0.4** 96.9 ± 6.2**
109.1 ± 2.2 120.8 ± 4.1* 133.3 ± 3.1*
decrease in cell viability.
Fig. 1. CAE attenuates Ab1e40-induced neurotoxicity. Differentiated PC12 (A) and IMR32 (B) cells were treated with varying concentrations of aggregated Ab1e40, and cell viability
was measured at 24 and 48 h after treatment. To determine the effect of CAE on Ab1e40 neurotoxicity, differentiated PC12 (C) and IMR32 (D) cells were treated with aggregated
Ab1e40 and CAE at indicated concentrations for 24 and 48 h, and cell viability was measured. In all experiments, cells left untreated served as controls. Values are expressed as
mean ± SD (n ¼ 6). *Signiﬁcantly different (P < 0.05) vs. the control group. #Signiﬁcantly different (P < 0.05) vs. the Ab1e40 treatment alone.
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control (P < 0.05 versus control; Fig. 3). Treatment of PC12 cells
with 25, 50, and 100 mg/mL CAE and Ab1e40 for 6 h reduced ROS
to normal levels (P < 0.05 versus Ab1e40 treatment alone);
however, this effect was no longer signiﬁcantly present after 24 h
(Fig. 3). These results suggested that CAE may only suppress the
induction of ROS at an early stage after aggregated Ab1e40
treatment.
3.4. Effect of CAE and Ab1e40 treatment on SOD and catalase
activities
A primary ROS in the human body is superoxide, which can
be generated by the effect of aggregated Ab1e40 on mitochon-
dria.18 Our data showed that after 24 h of aggregated Ab1e40
treatment, the SOD activity of differentiated PC12 and IMR32
cells was signiﬁcantly inhibited to approximately 90% and 60%
of control levels, respectively (P < 0.05 versus control; Fig. 4A
and B). However, CAE clearly reversed the inhibition of SOD
activity (P < 0.05 versus Ab1e40 treatment alone) caused by
aggregated Ab1e40. Additionally, CAE at concentrations of 25, 50,
and 100 mg/mL mediated the increase of SOD activity to normal
levels (Fig. 4A and B). Interestingly, SOD activities observed in
the presence of different concentrations of CAE did not demon-
strate any clear dose-dependence in PC12 cells, but ratherdemonstrated peak activation at the lowest dose (25 mg/mL). We
suggest that these results are attributable to complex compo-
nents of CAE, some of which are activating, while others are
inhibitory; at the lowest dose, the sum of all CAE-based effects
may be activating in nature (a hypothesis that requires further
examination).
Hydrogen peroxide, a primary ROS generated upon buildup
of aggregated Ab1e40 in cells, is converted to H2O and oxygen
by the action of catalase. As shown in Fig. 4C, when the
differentiated PC12 cells were treated with 8 mM aggregated
Ab1e40 for 24 h, catalase activity was signiﬁcantly reduced to
approximately 85% that of control (P < 0.05 versus control).
However, when the cells were cotreated with Ab1e40 and
CAE at concentrations of 25, 50, and 100 mg/mL, the reduction
in catalase activity observed in cells treated with Ab1e40 alone
was markedly reversed (P < 0.05 versus Ab1e40 treatment
alone) to 116.3%, 123.6%, and 129.6% of the control, respectively
(Fig. 4C).
When IMR32 cells were treated with 2.0 mM aggregated
Ab1e40 for 24 h, catalase activity was signiﬁcantly reduced to
approximately 66.3% that of control (P < 0.05 versus control,
Fig. 4D). However, when the cells were cotreated with CAE at
concentrations of 25, 50, and 100 mg/mL, the reduction in catalase
activity observed in cells treated with Ab1e40 alone was
markedly reversed (P < 0.05 versus Ab1e40 treatment alone) to
Fig. 2. Chromatogram of Centella asiatica (雷公根 lei gong gen) extracts in HPLC. (A)
Chromatogram of standards with HPLC method. (B) Chromatogram of Centella asiatica
extracts with the HPLC method. Standard solutions including madecoside (MS), asi-
aticoside (AS), madecassic acid (MA) and asiatic acid (AA).
Fig. 3. Effect of CAE on Ab1e40-induced ROS production. The ROS levels in differ-
entiated PC12 cells were measured after cotreatment with CAE and aggregated
Ab1e40. Cells left untreated served as the control. Relative ﬂuorescence
intensity ¼ (ﬂuorescence intensity of treatment/ﬂuorescence intensity of
control)  100. Values are expressed as mean ± SD (n ¼ 6). *P < 0.05 compared to
control, #P < 0.05 compared to Ab1e40 treatment alone.
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These ﬁndings suggest that CAE has the ability to modulate
catalase activity in the cell to reduce ROS generation caused by
Ab1e40 accumulation.3.5. Effect of CAE and Ab1e40 treatment on the glutathione system
GR and GPx are antioxidant enzymes that mediate the
breakdown of H2O2 into non-toxic products. GPx catalyzes the
transfer of electrons from GSH to GSSG, accompanied by the
conversion of H2O2 into water. By contrast, GR catalyzes the
digestion of GSSG into GSH, thereby providing sufﬁcient reactive
molecules for GPx activity. Our results indicated that the activ-
ities of GR and GPx after treatment with aggregated Ab1e40 for
24 h did not differ signiﬁcantly from those of the control (P < 0.05
versus control). However, after treatment with a combination of
Ab1e40 and varying concentrations of CAE (25, 50, and 100 mg/
mL), the activities of GR and GPx in differentiated PC12 cells were
signiﬁcantly enhanced to approximately GR 110% and GPx 112%
that of the Ab treatment (P < 0.05 versus Ab treatment alone;
Fig. 5A and C), while activities of GR and GPx in IMR32 cells were
signiﬁcantly enhanced to approximately GR 113% and GPx 117%
that of the Ab treatment (P < 0.05 versus Ab treatment alone;
Fig. 5B and D). This ﬁnding suggests that CAE could stimulate the
activities of GR and GPx in differentiated PC12 and IMR32 cells to
modulate oxidative stress in these cells, irrespective of whether
the activities of GR and GPx were affected by aggregated Ab1e40.
In addition, we measured the GSH/GSSG ratio, a strong indicator
of oxidative stress in the cells. The ratio of GSH/GSSG in the cells
was signiﬁcantly reduced after treatment with Ab1e40, from
approximately 31.5 to 18.3, and from approximately 34.5 to 19.3
in differentiated PC12 and IMR32 cells, respectively (Fig. 5E).
However, cotreatment with CAE resulted in a signiﬁcant increase
in the ratio of GSH/GSSG, from approximately 19.9 to 23.1 and
from approximately 21.3 to 30.2 in PC12 and IMR32 cells,
respectively (P < 0.05 versus Ab1e40 treatment alone). These re-
sults suggested that differentiated PC12 and IMR32 cells treated
with Ab1e40 were existing under conditions of high oxidative
stress, and treatment of CAE can reduces Ab1e40-induced toxicity
in neuronal cells.
4. Discussion
The Ab peptide Ab1e40, and Ab1e42 to an even greater extent, is a
critical factor in triggering AD. The primary mechanisms of Ab
peptide-mediated action in the development of AD involve re-
actions with metals, such as Cuþ or Fe2þ,19 or binding to receptors,
such as the N-methyl-D-aspartate (NMDA) receptor. Additionally,
after Ab enters the cell, it interferes with the electron transport
chain in mitochondria, leading to mitochondrial dysfunction and
the generation of excessive superoxide levels.20,21 In all these re-
spects, both Ab types could be classiﬁed as ROS inducers.
Plasma concentrations of both Ab1e40 and Ab1e42 increase with
age in individuals over the age of 65 years,22 in individuals who
carry mutations that cause early-onset familial AD,23 and in pa-
tients with Down's syndrome, who are at heightened risk of
developing AD.24 Additionally, plasma Ab levels are elevated in ﬁrst
degree relatives of peoplewith AD, who are also at an increased risk
of developing the disease.25 The plasma concentrations of Ab1e40
and Ab1e42 were associated with risk and subtypes of dementia, a
prospective population-based cohort study of men and women
aged 55 y and older.24 High plasma concentrations of Ab1e40 were
associated with an increased risk of dementia, particularly in in-
dividuals who have concomitantly low concentrations of Ab1e42;
these individuals had an over 10-fold increased risk of dementia
compared with individuals with low concentrations of both Ab1e40
and Ab1e42.26
In this study, we selected Ab1e40 as an inducer of neurotoxicity
in neuronal cells to investigate the relationship between CAE and
Fig. 4. Effect of CAE on SOD and catalase activities in Ab1e40-treated cells. SOD activity in differentiated PC12 (A) and IMR32 (B) cells was measured at 24 h after treatment with
aggregated Ab1e40 and CAE at indicated concentrations. Catalase activity in differentiated PC12 (C) and IMR32 (D) cells was measured at 24 h after treatment with aggregated Ab1e40
and CAE. In all experiments, cells left untreated served as controls. SOD and catalase activities were presented as a percentage of the control. Values are expressed as mean ± SD
(n ¼ 6). *P < 0.05 compared to control, #P < 0.05 compared to Ab1e40 treatment alone.
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Our data showed that the Ab1e40 peptide treatment resulted in a
marked elevation of ROS levels in differentiated PC12 cells, and
caused markedly elevated rates of cell death (Figs. 1AeD and 3),
suggesting that the model of Ab1e40 treatment in differentiated
PC12 cells could faithfully replicate ROS-related, Ab1e40-induced
neurotoxicity, and could function as a suitable platform for exam-
ining the role of CAE in Ab1e40-induced neurotoxicity. Ab1e40 trig-
gered the reduction of SOD and catalase activities (Fig. 4AeD), as
well as a decrease in the concentration of GSH (Fig. 5E). These re-
sults are consistent with the ﬁndings of previous studies showing
that aggregated Ab1e40 could damage the antioxidative defence
system in cells, particularly in neurons.27 These ﬁndings also
conﬁrm that our selection of Ab1e40 for investigating the anti-
oxidative defence system was appropriate.
In the current study, we showed that treatment with CAE
greatly facilitated the recovery of cells from Ab1e40-induced
neurotoxicity (Fig. 1C and D). Mechanism by which CAE inhibits
Ab1e40-induced neurotoxicity at least partially involves activation
of the antioxidative enzymes (Figs. 4e6). CAE signiﬁcantly
reduced the ROS level upon cotreatment with Ab1e40 at 6 h. This
result suggests that CAE not only modulates the antioxidative
defence system, but also protects the cell from Ab1e40-inducedneurotoxicity by direct elimination of imbalanced ROS production
at an early stage (Fig. 3). Previous studies have shown that C.
asiatica (雷公根 lei gong gen) extracts, including both aqueous and
ethanolic extracts, possess DPPH radical-scavenging capability
and high reducing potential.11 Thus, we propose that CAE can
protect neuronal cells against Ab1e40-induced neurotoxicity via
multiple mechanisms, which together may account for the
observation that CAE improves behavioral symptoms in the mouse
AD model.15
Several strategies have been proposed to treat AD; for
example, the use of pharmaceuticals that target the acetylcholine
system28; compounds that clear the deposition of Ab or interrupt
the generation of Ab29,30; and antioxidants that reduce ROS levels
or elevate the antioxidative defence system to protect neurons
from Ab-induced toxicity.8,9 We believe that a common thread
among all these strategies for the prevention and cure of AD is the
primary importance ascribed to neuronal protection, particularly
by enhancing the antioxidative defence system. Because most
other strategies primarily focus on more advanced stages of AD
and on managing symptoms of AD, their therapeutic efﬁcacy
cannot assist patients with AD to fully return to a normal life.
Only by elevating the capacity of the antioxidative defence sys-
tem can the goal of preventing AD or other ROS-related diseases
Fig. 5. Effect of CAE on the glutathione system in Ab1e40-treated cells. Differentiated PC12 (A, C) and IMR32 cells (B, D) were treated with aggregated Ab1e40 and CAE at indicated
concentrations for 24 h, and GR (A, B) and GPx (C, D) activities were measured. GR and GPx activities are displayed as a percentage of the control. (E) The GSH/GSSG ratio in
differentiated PC12 (-) and IMR32 (▫) cells were measured at 24 h after cotreatment with CAE and aggregated Ab1e40. In all experiments, cells left untreated served as controls.
Values are expressed as mean ± SD (n ¼ 6). *P < 0.05 compared to control, #P < 0.05 compared to Ab1e40 treatment alone.
C.-L. Chen et al. / Journal of Traditional and Complementary Medicine 6 (2016) 362e369368be achieved. We observed a strong correlation between CAE and
activation of the antioxidative defence system. However, CAE may
prevent AD development, not only by simply activating the
antioxidative defence system, but also by possessing the capa-
bility to directly eliminate ROS or to interfere with Abaccumulation, as suggested by the reduction of the Ab1e42 and
Ab1e40 deposition in transgenic mice administered CAE.14
Therefore, CAE possesses great potential for being developed
into a functional food consumed to suppress or prevent AD,
although this requires additional in vivo studies.
Fig. 6. The mechanism of Centella asiatica extracts against Ab1e40 neurotoxicity.
C.-L. Chen et al. / Journal of Traditional and Complementary Medicine 6 (2016) 362e369 3695. Conclusion
Our ﬁndings suggest that CAE can suppress Ab-induced neuro-
toxicity by enhancing the antioxidative defence system in differ-
entiated PC12 and IMR32 cells and provides a plausible basis for the
development of therapeutic treatment or prophylaxis for AD.Conﬂicts of interest
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